Denosumab
| Klinički podaci | |
|---|---|
| Prodajno ime | Prolia, Ranmark, Xgeva |
| Drugs.com | Monografija |
| Način primene | Subkutano |
| Farmakokinetički podaci | |
| Poluvreme eliminacije | 25,4 dana |
| Identifikatori | |
| CAS broj | 615258-40-7  |
| ATC kod | M05BX04 (WHO) |
| DrugBank | DB06643 |
| ChEMBL | CHEMBL1237023 |
| Hemijski podaci | |
| Formula | C6404H9912N1724O2004S50 |
| Molarna masa | 144.7 |
Denosumab[1] je ljudsko monoklonalno antitelo za tretman ostioporoze, gubitka koštane mase, koštanih metastaza, multiplog mijeloma, i tumora gigantskih ćelija kostiju.[2][3] Ovaj lek je razvilo biotehnološko preduzeće Amgen.[4] Denosumab je IgG2 monoklonalno antitelo koje je inhibira RANKL ligand.[5][6][7]
Reference[uredi | uredi izvor]
- ^ Pageau, Steven C. (2009). „Denosumab”. MAbs. 1 (3): 210—215. PMC 2726593
. PMID 20065634. doi:10.4161/mabs.1.3.8592.
- ^ McClung, Michael R.; Lewiecki, E. Michael; Cohen, Stanley B.; Bolognese, Michael A.; Woodson, Grattan C.; Moffett, Alfred H.; Peacock, Munro; Miller, Paul D.; Lederman, Samuel N. (2006). „Denosumab in Postmenopausal Women with Low Bone Mineral Density”. New England Journal of Medicine. 354 (8): 821—31. PMID 16495394. doi:10.1056/NEJMoa044459.
- ^ Ellis, G. K.; Bone, H. G.; Chlebowski, R.; Paul, D.; Spadafora, S.; Smith, J.; Fan, M.; Jun, S. (2008). „Randomized Trial of Denosumab in Patients Receiving Adjuvant Aromatase Inhibitors for Nonmetastatic Breast Cancer”. Journal of Clinical Oncology. 26 (30): 4875—82. PMID 18725648. doi:10.1200/JCO.2008.16.3832.
- ^ „Prolia (denosumab)”. Products. Amgen. Архивирано из оригинала 29. 09. 2015. г. Приступљено 6. 5. 2012.
- ^ Malan J, Ettinger K, Naumann E, Beirne OR: The relationship of denosumab pharmacology and osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 Dec;114(6):671-6. doi: 10.1016/j.oooo.2012.08.439. PMID 23159111
- ^ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035—41. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.
- ^ David S. Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic acids research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.
Literatura[uredi | uredi izvor]
- Walker, Emily P. (7. 2. 2012). „Benefit of Bone Drug in Prostate Cancer in Doubt”. MedPage Today.
- Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
- Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.
Spoljašnje veze[uredi | uredi izvor]
 | Molimo Vas, obratite pažnju na važno upozorenje u vezi sa temama iz oblasti medicine (zdravlja). |
